Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 60–61

HOS-112205 · Präparat HOS-093615

60 Medicinal products by Interaction Recommendations therapeutic area concerning co-administration SEDATIVES Benzodiazepines Midazolam Midazolam and triazolam are extensively Co-administration of Triazolam metabolised by CYP3A4. Co- REYATAZ with triazolam or administration with REYATAZ may cause orally administered midazolam a large increase in the concentration of is contraindicated (see these benzodiazepines. No drug interaction section 4.3), whereas caution study has been performed for the co- should be used with co- administration of REYATAZ with administration of REYATAZ benzodiazepines. Based on data for other and parenteral midazolam. If CYP3A4 inhibitors, plasma concentrations REYATAZ is co-administered of midazolam are expected to be with parenteral midazolam, it significantly higher when midazolam is should be done in an intensive given orally. Data from concomitant use of care unit (ICU) or similar parenteral midazolam with other protease setting which ensures close inhibitors suggest a possible 3-4-fold clinical monitoring and increase in midazolam plasma levels. appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) triazolam (HOS-086168) midazolam (HOS-086167)